Rani Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results; Provides Corporate Update
- Announced preclinical data demonstrating the bioequivalence of RT-114, a GLP-1/GLP-2 dual agonist (PG-102) delivered orally via the RaniPill$(R)$ capsule, to subcutaneous administration of PG-102 -
- Announced preclinical data demonstrating successful oral delivery of semaglutide via RaniPill(R) capsule -
- Preclinical data of four incretin-based molecules underscores the RaniPill(R) platform's potential to facilitate the oral delivery of a diverse array of obesity treatments -
- Phase 1 study for RT-114 for the treatment of obesity, expected to initiate in mid-2025 -
- Conference call today at 4:30 p.m. ET / 1:30 p.m. PT -
SAN JOSE, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. ("Rani Therapeutics" or "Rani") (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today reported financial results for the quarter and full year ended December 31, 2024 and provided a corporate update.
"We entered 2025 with strong momentum, delivering compelling preclinical data demonstrating the successful delivery of multiple obesity treatments. Our preclinical studies show that RT-114, the RaniPill(R) capsule containing a GLP-1/GLP-2 dual agonist (PG-102), delivered pharmacokinetics, weight loss, and bioavailability comparable to PG-102 administered via subcutaneous injection. Additionally, last month, we shared preclinical data confirming that semaglutide delivered via the RaniPill(R) capsule exhibits similar bioavailability, pharmacokinetics, and weight loss as subcutaneous administration," said Talat Imran, Chief Executive Officer of Rani Therapeutics. "Overall, we are encouraged by our robust preclinical data package across four incretin-based molecules, which highlights the RaniPill(R) platform's potential to effectively enable the oral delivery of multiple obesity treatments, paving the way for more convenient and accessible therapeutic options. Moreover, we are confident that RT-114 has the potential to become a first-in-class, orally administered GLP-1/GLP-2 dual agonist for the treatment of obesity, addressing a crucial gap in the current treatment landscape. As we look ahead, we intend to initiate a Phase 1 study of RT-114 later this year."
Fourth Quarter and Full Year 2024 Highlights:
-- Positive topline results from phase 1 study of an oral anti-interleukin
12/23 antibody (RT-111). In February 2024, Rani announced RT-111 achieved
high bioavailability and was well tolerated, with no serious adverse
events in humans in a Phase 1 study.
-- Presentation of clinical and preclinical data on oral delivery of an
ustekinumab biosimilar via the RaniPill(R) capsule at Digestive Disease
Week 2024. In May 2024, Rani presented preclinical and clinical data
demonstrating the delivery of RT-111 with comparable bioavailability
relative to subcutaneous (SC) injection of ustekinumab in canines and
healthy human participants, respectively.
-- Partnership with ProGen on development of oral obesity treatment. In June
2024, Rani announced that it had entered into a definitive agreement with
ProGen Co., Ltd., a South Korean clinical-stage biotech company
developing next generation long-acting, multi-specific fusion protein
therapeutics, for the co-development and commercialization of RT-114, an
oral RaniPill(R) capsule containing ProGen's PG-102, a GLP-1/GLP-2 dual
agonist, for the treatment of obesity.
-- Completed two equity offerings for total gross proceeds of approximately
$20.0 million. In July and October 2024, Rani completed the sale and
issuance of Class A common stock, pre-funded warrants to purchase Class A
common stock, and warrants to purchase Class A common stock, to an
institutional investor for total gross proceeds of approximately $20.0
million, excluding any potential proceeds from the exercise of warrants,
if any.
-- Preclinical pharmacokinetic data supporting transenteric delivery of
GLP-1 incretin triagonist. In October 2024, Rani announced new
pharmacokinetic data from a preclinical study evaluating a GLP-1, GIP and
glucagon receptors incretin triagonist with a delivery method mimicking
the RaniPill(R) route of administration. The data demonstrated that
transenteric delivery of incretin triagonist GLP-1, GIP, glucagon
receptors elicited rapid weight loss and bioavailability comparable to
subcutaneous injection.
-- Preclinical data demonstrating successful oral delivery of semaglutide
via RaniPill(R) HC. In February 2025, Rani released preclinical data that
demonstrated semaglutide administered orally via the RaniPill(R) HC
(RT-116) resulted in comparable bioavailability, pharmacokinetics and
weight loss to subcutaneous administration of semaglutide. RT-116 was
well tolerated with no serious adverse events. Data adds to growing body
of evidence of the RaniPill(R) platform's potential to enable oral
delivery of multiple obesity treatments.
-- Preclinical data demonstrating bioequivalence of RT-114, a GLP-1/GLP-2
dual agonist (PG-102) delivered orally via the RaniPill(R) capsule, to
subcutaneously administered PG-102. In March 2025, Rani released new
preclinical data, where RT-114 yielded a relative bioavailability of 111%
compared to PG-102 delivered subcutaneously with comparable
pharmacokinetic profiles demonstrating bioequivalence.
Near-Term Milestone Expectations:
-- Initiation of Phase 1 clinical trial of RT-114 for the treatment of
obesity expected in mid-2025.
Fourth Quarter and Full Year 2024 Financial Results:
-- Cash, cash equivalents and marketable securities as of December 31, 2024
totaled $27.6 million, compared to $48.5 million for the year ended
December 31, 2023. Rani expects its cash, cash equivalents and marketable
securities to be sufficient to fund its operations into the third quarter
of 2025 without additional funding.
-- Contract Revenue for the three and twelve months ended December 31, 2024
were $1.0 million and was attributable to evaluation services performed
for a customer. There was no contract revenue for the same periods in
2023.
-- Research and development expenses for the three and twelve months ended
December 31, 2024 were $6.8 million and $26.7 million, respectively,
compared to $7.6 million and $39.6 million for the same periods in 2023,
respectively. The year over year decrease of $12.9 million was primarily
attributable to lower compensation costs of $6.3 million due to reduction
in workforce, $5.6 million reduction in third-party services and $0.9
million reduction in materials and supplies due to the timing of certain
preclinical and clinical studies.
-- General and administrative expenses for the three and twelve months ended
December 31, 2024 were $5.5 million and $23.9 million, respectively,
compared to $5.8 million and $26.5 million for the same periods in 2023,
respectively. The year over year decrease of $2.5 million was primarily
attributable to lower compensation costs of $2.0 million due to reduction
in workforce, $1.2 million reduction in third-party services and other
costs primarily due to lower insurance premiums, offset by an increase in
facility costs of $0.7 million due to the lease in Fremont, California.
-- Impairment Loss for the three and twelve months ended December 31, 2024
were $3.7 million and was attributable to construction-in-progress
property and equipment. Rani considers many factors in evaluating whether
the value of its construction-in-progress property and equipment may not
be recoverable, including, but not limited to, alternative use,
cost-savings and strategic considerations. As a result, it was determined
that the carrying amount of the construction-in-progress property and
equipment exceeded its fair value and was written down to its salvage
value. There was no impairment loss for the same periods in 2023.
-- Net loss for the three and twelve months ended December 31, 2024 were
$15.7 million and $56.6 million, respectively, compared to $14.1 million
and $67.9 million for the same period in 2023, respectively, including
non-cash stock-based compensation expense of $4.0 million for the three
months ended December 31, 2024 and $16.0 million for the full year 2024,
compared to $4.5 million and $19.0 million for the same periods in 2023,
respectively. The net loss for the three and twelve months ended December
31, 2024 also includes the non-cash impairment loss of $3.7 million, as
described above.
Conference Call
Rani will host a corresponding conference call today at 4:30 p.m. ET / 1:30 p.m. PT to discuss the results and provide a business update. Individuals interested in listening to the live conference call may do so by using the link in the "Investors" section of the company's website at www.ranitherapeutics.com. A webcast replay will be available in the investor relations section on the company's website following the completion of the call.
About Rani Therapeutics
Rani Therapeutics is a clinical-stage biotherapeutics company focused on advancing technologies to enable the development of orally administered biologics and drugs. Rani has developed the RaniPill(R) capsule, which is a novel, proprietary and patented platform technology, intended to replace subcutaneous injection or intravenous infusion of biologics and drugs with oral dosing. Rani has successfully conducted several preclinical and clinical studies to evaluate safety, tolerability and bioavailability using RaniPill(R) capsule technology. For more information, visit ranitherapeutics.com.
Forward-Looking Statements
Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include statements regarding, among other things, the expected initiation of a Phase 1 trial of RT-114 in mid-2025, the potential of the RaniPill(R) platform to enable oral delivery of multiple obesity treatments and validation of such potential through preclinical data, the potential of the RaniPill(R) platform to offer more convenient and accessible therapeutic options, the potential for RT-114 to become a first-in-class, orally administered GLP-1/GLP-2 dual agonist for the treatment of obesity, the sufficiency of Rani's cash reserves, the timing and extent of its expenses, and future financial performance. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as "confident, " "intend," "potential," "expect," and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Rani's current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks and uncertainties associated with Rani's business in general and the other risks described in Rani's filings with the Securities and Exchange Commission, including Rani's annual report on Form 10-K for the year ended December 31, 2024, and subsequent filings and reports by Rani. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management's assumptions and estimates as of such date. Rani undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.
Investor Contact:
investors@ranitherapeutics.com
Media Contact:
media@ranitherapeutics.com
RANI THERAPEUTICS HOLDINGS, INC.
CONSOLIDATED BALANCE SHEETS
(In thousands, except par value)
December 31,
--------------------
2024 2023
--------- --------
Assets
Current assets:
Cash and cash equivalents $ 3,762 $ 5,864
Contract asset 428 --
Marketable securities 23,877 42,675
Prepaid expenses and other current assets 1,677 2,308
-------- -------
Total current assets 29,744 50,847
Property and equipment, net 1,548 6,105
Operating lease right-of-use asset 5,096 718
Other assets 246 246
-------- -------
Total assets $ 36,634 $ 57,916
======== =======
Liabilities and Stockholders' Equity
Current liabilities:
Accounts payable $ 1,359 $ 648
Accrued expenses and other current
liabilities 2,073 1,726
Current portion of long-term debt 15,000 4,897
Current portion of operating lease
liability 1,459 718
-------- -------
Total current liabilities 19,891 7,989
Long-term debt, less current portion 9,613 24,484
Operating lease liability, less current
portion 3,637 --
-------- -------
Total liabilities 33,141 32,473
-------- -------
Stockholders' equity:
Preferred stock, $0.0001 par value - 20,000
shares authorized; none issued and
outstanding as of December 31, 2024 and
December 31, 2023 -- --
Class A common stock, $0.0001 par value -
800,000 shares authorized; 33,430 and 26,036
issued and outstanding as of December 31,
2024 and December 31, 2023, respectively 3 3
Class B common stock, $0.0001 par value -
40,000 shares authorized; 23,972 and 24,116
issued and outstanding as of December 31,
2024 and December 31, 2023, respectively 2 2
Class C common stock, $0.0001 par value -
20,000 shares authorized; none issued and
outstanding as of December 31, 2024 and
December 31, 2023 -- --
Additional paid-in capital 104,889 85,762
Accumulated other comprehensive gain
(loss) 5 (12)
Accumulated deficit (102,907) (72,889)
-------- -------
Total stockholders' equity attributable to
Rani Therapeutics Holdings, Inc. 1,992 12,866
Non-controlling interest 1,501 12,577
-------- -------
Total stockholders' equity 3,493 25,443
-------- -------
Total liabilities and stockholders'
equity $ 36,634 $ 57,916
======== =======
RANI THERAPEUTICS HOLDINGS, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands, except per share amounts)
Three Months Ended Year Ended December
December 31, 31,
-------------------- --------------------
2024 2023 2024 2023
-------- --------- -------- ---------
Contract revenue $ 1,028 $ -- $ 1,028 $ --
Operating expenses
Research and
development 6,810 7,606 26,682 39,624
General and
administrative 5,462 5,829 23,946 26,475
Impairment loss 3,714 -- 3,714 --
------- -------- ------- --------
Total
operating
expenses $ 15,986 $ 13,435 $ 54,342 $ 66,099
------- -------- ------- --------
Loss from
operations (14,958) (13,435) (53,314) (66,099)
Other income
(expense), net
Interest income
and other, net 361 676 1,763 3,301
Interest expense
and other, net (1,124) (1,296) (5,033) (5,085)
------- -------- ------- --------
Net loss $(15,721) $ (14,055) $(56,584) $ (67,883)
Net loss
attributable to
non-controlling
interest (6,775) (6,956) (26,566) (33,913)
------- -------- ------- --------
Net loss
attributable to
Rani Therapeutics
Holdings, Inc. $ (8,946) $ (7,099) $(30,018) $ (33,970)
======= ======== ======= ========
Net loss per
Class A common
share
attributable to
Rani
Therapeutics
Holdings, Inc.,
basic and
diluted $ (0.27) $ (0.27) $ (1.05) $ (1.33)
======= ======== ======= ========
Weighted-average
Class A common
shares
outstanding--basic
and diluted 32,660 25,874 28,476 25,505
======= ======== ======= ========
(END) Dow Jones Newswires
March 31, 2025 16:05 ET (20:05 GMT)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.